MedTrace Logo

Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma

NCT02428764 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-12-10

No results posted yet for this study

Summary

The purpose of this study is studying induction nimotuzumab plus gemcitabine and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III squamous cell lung carcinoma.

Conditions

Interventions

DRUG

Nimotuzumab

Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8

DRUG

Gemcitabine

Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.

DRUG

Carboplatin

carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.

PROCEDURE

Surgery

Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Si-Yu Wang, MD · Guangdong Province Association Study of Thoracic Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-01
Primary Completion
2025-10-01
Completion
2027-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02428764 on ClinicalTrials.gov